Drug
Zanamivir clinical trials
Also written Relenza.
- studies test it
- 16
- open now
- 2
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the Zanamivir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2011 | 3 |
| 2012 | 1 |
| 2015 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
GlaxoSmithKline (7) · University of Missouri-Columbia (1) · Mount Sinai Hospital, Canada (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · George Washington University (1) · University of Oxford (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Oseltamivir (6) · Influenza Vaccines (1) · Favipiravir (1) · Baloxavir (1) · Molnupiravir (1) · Peramivir (1) · Laninamivir (1) · Amantadine (1)
Studies
Open first, then newest update. How each study uses Zanamivir is read from its arms, and is right about nine times in ten.
Testing it · 16
- Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)RecruitingPhase 2George Washington UniversityNCT04597437Written as Zanamivir
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaRecruitingPhase 2University of OxfordNCT05648448Written as Zanamivir
- An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza InfectionCompletedPhase 2GlaxoSmithKlineNCT04494412Written as Zanamivir
- Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 DiabetesCompletedPhase 2University of Missouri-ColumbiaNCT04867707Written as Zanamivir
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaCompletedPhase 3GlaxoSmithKlineNCT01231620Written as Zanamivir
- A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionCompletedPhase 3GlaxoSmithKlineNCT01527110Written as Intravenous (IV) zanamivir
- Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese MalesCompletedPhase 1GlaxoSmithKlineNCT01428479Written as GR121167 Solution
- Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 DaysCompletedPhase 1GlaxoSmithKlineNCT00989404Written as Zanamivir
- Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese AdultsCompletedPhase 1GlaxoSmithKlineNCT02377401Written as Zanamivir
- Zanamivir Versus Trivalent Split Virus Influenza VaccineCompletedPhase 3Mount Sinai Hospital, CanadaNCT00784784Written as Zanamivir
- Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in ChinaCompletedPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01459081Written as Zanamivir
- Evaluation of Efficacity and Safety of Oseltamivir and ZanamivirTerminatedPhase 3Assistance Publique - Hôpitaux de ParisNCT00799760Written as oseltamivir + zanamivir
- A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza InfectionTerminatedPhase 3Chinese University of Hong KongNCT00979667Written as Zanamivir
- Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A InfectionTerminatedPhase 2Hospices Civils de LyonNCT00830323Written as oseltamivir + zanamivir
- A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy SubjectsWithdrawnPhase 1GlaxoSmithKlineNCT00540501Written as Oseltamivir and Intravenous Zanamivir
- Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00921726Written as Zanamivir
As the comparator · 1 — what is tested is compared with Zanamivir
Codes
What other systems call Zanamivir · ClinicalTrials.gg INT008881
- MeSH (NLM) D053243ZanamivirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) L6O3XI777IZANAMIVIRConfirmed FDA, NLM, Wikidata
- RxNorm 69722Confirmed FDA, Wikidata
- Wikidata Q146075zanamivirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47786ZanamivirOne source FDA
- DrugBank DB00558One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D053243 | Zanamivir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | L6O3XI777I | ZANAMIVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 69722 | — | Confirmed FDA, Wikidata |
| Wikidata | Q146075 | zanamivir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47786 | Zanamivir | One source FDA |
| DrugBank | DB00558 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.